Form 4: Co-Diagnostics CEO, Dwight H. Egan, Executes Stock Transactions Following RSU Vesting

Co-Diagnostics CEO, Dwight H. Egan, acquired 163,333 shares of common stock through vesting of restricted stock units and sold 49,689 shares to cover tax obligations.

Summary

• Dwight H. Egan, CEO of Co-Diagnostics, Inc., acquired 163,333 shares of common stock on November 23, 2024, through the vesting of restricted stock units (RSUs).
• These RSUs are part of grants made on June 6, 2022, January 17, 2023, May 15, 2023, and April 26, 2024, under the company's 2015 Long Term Incentive Plan.
• The RSUs vest in six equal installments every six months, with the latest vesting occurring on November 23, 2024.
• To cover tax withholding obligations associated with the vesting, Mr. Egan sold 49,689 shares of common stock at a price of $1.01 per share.
• This sale was not a discretionary trade but a mandatory action by the company to cover tax obligations.
• Following these transactions, Mr. Egan directly owns 522,858 shares of Co-Diagnostics common stock.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction related to executive compensation. While the sale of shares might be perceived slightly negatively, it is a standard practice for tax obligations and does not indicate any significant negative sentiment.

Positives

• The vesting of restricted stock units indicates that the CEO is meeting the conditions of the company's long-term incentive plan.
• The CEO's continued ownership of a significant number of shares aligns his interests with those of the shareholders.

Negatives

• The sale of shares, even if for tax purposes, could be perceived negatively by some investors as a reduction in the CEO's stake.

Risks

• The sale of shares by the CEO, even for tax purposes, could potentially create short-term selling pressure on the stock.
• The reliance on 'sell to cover' transactions for tax obligations could lead to further sales of shares by executives in the future.

Management Comments

• The sale of shares was mandated by the Issuer's election, under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary trade by the Reporting Person.

Industry Context

This type of stock transaction is common for executives who receive equity-based compensation, particularly in companies that use restricted stock units as part of their incentive plans. The 'sell to cover' mechanism is a standard practice to manage tax obligations.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as part of executive compensation is a common practice across many industries, including biotechnology and diagnostics, similar to companies like Exact Sciences (EXAS) and Bio-Rad Laboratories (BIO).
• The vesting schedules of RSUs, typically over several years with periodic vesting dates, are also standard practice to align executive interests with long-term company performance, similar to the vesting schedules used by companies like Illumina (ILMN).
• The 'sell to cover' mechanism for tax obligations is a widely used method to manage the tax implications of RSU vesting, and is a common practice across many companies, including those in the technology sector like Apple (AAPL) and Microsoft (MSFT).

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares, but it is a standard practice for tax obligations.
• The vesting of RSUs is a positive for the executive, aligning their interests with the company's long-term performance.

Key Dates

Keywords

Co-Diagnostics, Dwight H. Egan, restricted stock units, RSU, stock transaction, insider trading, executive compensation, tax withholding, equity incentive plan